CN1628646A - 酒石酸托特罗定的分散片剂型 - Google Patents
酒石酸托特罗定的分散片剂型 Download PDFInfo
- Publication number
- CN1628646A CN1628646A CN 200410057363 CN200410057363A CN1628646A CN 1628646 A CN1628646 A CN 1628646A CN 200410057363 CN200410057363 CN 200410057363 CN 200410057363 A CN200410057363 A CN 200410057363A CN 1628646 A CN1628646 A CN 1628646A
- Authority
- CN
- China
- Prior art keywords
- tolterodine tartrate
- tablet
- tolterodine
- disintegrating agent
- tablet formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229960003553 tolterodine tartrate Drugs 0.000 title claims abstract description 43
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 title claims 5
- 235000002906 tartaric acid Nutrition 0.000 title 1
- 239000011975 tartaric acid Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000000654 additive Substances 0.000 claims abstract 3
- 230000000996 additive effect Effects 0.000 claims abstract 3
- 239000007919 dispersible tablet Substances 0.000 claims description 20
- 239000007916 tablet composition Substances 0.000 claims description 17
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 229960004045 tolterodine Drugs 0.000 claims description 4
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 4
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001634 Copolyester Polymers 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- -1 IRP-88 Polymers 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 150000001261 hydroxy acids Chemical class 0.000 claims description 2
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 11
- 206010046543 Urinary incontinence Diseases 0.000 abstract description 8
- 230000027939 micturition Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 239000006185 dispersion Substances 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 13
- 239000000945 filler Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000000314 lubricant Substances 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 10
- 230000001186 cumulative effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000005946 Xerostomia Diseases 0.000 description 6
- 206010013781 dry mouth Diseases 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- 210000003681 parotid gland Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 229960000855 flavoxate Drugs 0.000 description 1
- SPIUTQOUKAMGCX-UHFFFAOYSA-N flavoxate Chemical compound C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 SPIUTQOUKAMGCX-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940105346 tolterodine tartrate 2 mg Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Abstract
Description
时间(min) | 5 | 10 | 15 | 20 | 25 | 30 |
累积溶出度(%) | 62 | 73 | 84 | 95 | 97 | 99 |
分散时限 | 2.7min崩解,并可全部通过2号筛 |
时间(min) | 5 | 10 | 15 | 20 | 25 | 30 |
累积溶出度(%) | 66 | 74 | 85 | 95 | 99 | 99 |
分散时限 | 2.1min崩解,并可全部通过2号筛 |
时间(min) | 5 | 10 | 15 | 20 | 25 | 30 |
累积溶出度(%) | 71 | 85 | 94 | 97 | 97 | 97 |
分散时限 | 1.6min崩解,并可全部通过2号筛 |
时间(min) | 5 | 10 | 15 | 20 | 25 | 30 |
累积溶出度(%) | 78 | 89 | 95 | 95 | 97 | 97 |
分散时限 | 1.1min崩解,并可全部通过2号筛 |
时间(min) | 5 | 10 | 15 | 20 | 25 | 30 |
累积溶出度(%) | 83 | 91 | 95 | 99 | 99 | 99 |
分散时限 | 0.8min崩解,并可全部通过2号筛 |
时间(min) | 5 | 10 | 15 | 20 | 25 | 30 |
累积溶出度(%) | 85 | 93 | 97 | 97 | 99 | 99 |
分散时限 | 0.6min崩解,并可全部通过2号筛 |
时间(min) | 5 | 10 | 15 | 20 | 25 | 30 |
累积溶出度(%) | 89 | 94 | 95 | 97 | 97 | 97 |
分散时限 | 0.4min崩解,并可全部通过2号筛 |
时间(min) | 5 | 10 | 15 | 20 | 25 | 30 |
累积溶出度(%) | 91 | 95 | 99 | 99 | 99 | 99 |
分散时限 | 0.2min崩解,并可全部通过2号筛 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100573635A CN100382794C (zh) | 2004-08-30 | 2004-08-30 | 酒石酸托特罗定的分散片剂型 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100573635A CN100382794C (zh) | 2004-08-30 | 2004-08-30 | 酒石酸托特罗定的分散片剂型 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1628646A true CN1628646A (zh) | 2005-06-22 |
CN100382794C CN100382794C (zh) | 2008-04-23 |
Family
ID=34846198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100573635A Expired - Fee Related CN100382794C (zh) | 2004-08-30 | 2004-08-30 | 酒石酸托特罗定的分散片剂型 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100382794C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1330297C (zh) * | 2005-07-04 | 2007-08-08 | 宛六一 | 酒石酸托特罗定软胶囊及其制备方法 |
CN105832685A (zh) * | 2016-05-25 | 2016-08-10 | 南京正科医药股份有限公司 | 一种酒石酸托特罗定片 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0924983A4 (en) * | 1996-07-19 | 1999-08-25 | Gunnar Aberg | S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS |
EE05191B1 (et) * | 1999-11-11 | 2009-08-17 | Pharmacia Ab | Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine |
MXPA04002496A (es) * | 2001-09-27 | 2004-05-31 | Pharmacia Ab | Composicion farmaceutica para el tratamiento de enfermedades urinarias. |
-
2004
- 2004-08-30 CN CNB2004100573635A patent/CN100382794C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1330297C (zh) * | 2005-07-04 | 2007-08-08 | 宛六一 | 酒石酸托特罗定软胶囊及其制备方法 |
CN105832685A (zh) * | 2016-05-25 | 2016-08-10 | 南京正科医药股份有限公司 | 一种酒石酸托特罗定片 |
Also Published As
Publication number | Publication date |
---|---|
CN100382794C (zh) | 2008-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1101187C (zh) | 氟西汀药物制剂 | |
CN100335046C (zh) | 组合物 | |
CN1245972C (zh) | 柚皮素及其盐用于制备止咳化痰药物 | |
CN100341504C (zh) | 佐米曲普坦速释制剂 | |
CN1973836A (zh) | 一种治疗痛经的亲水性巴布剂 | |
CN1628646A (zh) | 酒石酸托特罗定的分散片剂型 | |
CN1287792C (zh) | 孟鲁司特钠的分散片剂型 | |
CN1803128A (zh) | 含有***马多和对乙酰氨基酚的口崩片及其制备方法 | |
CN1416881A (zh) | 一种抗抑郁的药物组合物及其制备方法 | |
CN1179726C (zh) | 柚皮苷在制备支持性治疗非典型性肺炎药物中的应用 | |
CN1903351A (zh) | 妇宁凝胶剂及其制备方法 | |
CN1175811C (zh) | 阿尼西坦缓释片 | |
CN1214793C (zh) | 一种用于中枢镇痛的鼻腔给药制剂 | |
CN1416880A (zh) | 四逆散及其活性部位的新用途 | |
CN1528292A (zh) | 辛伐他汀滴丸及其制备方法 | |
CN1582908A (zh) | ***马多滴丸及其制备方法 | |
CN1563075A (zh) | 一种用于治疗肝纤维化的丹参总酚酸的制备方法 | |
CN1309376C (zh) | 麝香缓、控释制剂及其制备方法 | |
CN1634066A (zh) | 盐酸阿夫唑嗪分散片 | |
CN1287795C (zh) | 阿昔莫司分散片剂型 | |
CN1270703C (zh) | 盐酸非洛普的缓释制剂及其制备方法 | |
CN1686166A (zh) | 治疗血管类疾病的药物组合物、其制备方法及其用途 | |
CN1528300A (zh) | 草乌甲素滴丸及其制备方法 | |
CN1528321A (zh) | 天麻素滴丸及其制备方法 | |
CN1568979A (zh) | 盐酸洛非西定滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000513 Denomination of invention: Dispersed tablet of tartaric acid tolterodine tartrate Granted publication date: 20080423 License type: Exclusive License Open date: 20050622 Record date: 20100909 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000513 Date of cancellation: 20131016 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161214 Address after: 276005 Hongqi Road, Shandong, Linyi, No. 209 Patentee after: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Address before: 276005 Hongqi Road, Shandong, Linyi, No. 209 Patentee before: LUNAN PHARMACEUTICAL Group Corp. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080423 |